Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eleven analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $18.30.
Several equities research analysts have recently issued reports on YMAB shares. Truist Financial lowered their price objective on Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. HC Wainwright dropped their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a "buy" rating and a $17.00 target price on the stock. Bank of America dropped their price target on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Wednesday, March 5th. Finally, Morgan Stanley reduced their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, March 5th.
Read Our Latest Report on YMAB
Y-mAbs Therapeutics Trading Down 3.0 %
YMAB traded down $0.15 during trading hours on Wednesday, hitting $4.81. The company's stock had a trading volume of 164,220 shares, compared to its average volume of 333,807. The stock has a market cap of $217.50 million, a price-to-earnings ratio of -8.91 and a beta of 0.65. The business's 50-day moving average price is $5.58 and its 200-day moving average price is $9.49. Y-mAbs Therapeutics has a 12 month low of $4.25 and a 12 month high of $17.78.
Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. During the same quarter last year, the firm earned ($0.02) earnings per share. On average, analysts forecast that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.
Insider Activity at Y-mAbs Therapeutics
In other news, insider Thomas Gad sold 10,810 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now owns 202,721 shares in the company, valued at approximately $1,060,230.83. This trade represents a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 22.50% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acorn Capital Advisors LLC purchased a new stake in shares of Y-mAbs Therapeutics in the 4th quarter worth approximately $22,408,000. Caligan Partners LP raised its stake in Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company's stock worth $15,718,000 after buying an additional 613,175 shares in the last quarter. State Street Corp lifted its holdings in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company's stock worth $15,909,000 after buying an additional 405,169 shares during the period. Infinitum Asset Management LLC bought a new stake in Y-mAbs Therapeutics during the 4th quarter valued at $1,218,000. Finally, Paradigm Biocapital Advisors LP increased its holdings in shares of Y-mAbs Therapeutics by 3.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company's stock valued at $33,171,000 after acquiring an additional 150,000 shares during the period. 70.85% of the stock is currently owned by institutional investors.
About Y-mAbs Therapeutics
(
Get Free ReportY-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
See Also
Before you consider Y-mAbs Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Y-mAbs Therapeutics wasn't on the list.
While Y-mAbs Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
